IGF2 and breast carcinoma: Among various breast cancer subtypes, including luminal (n = 8), HER2 (n = 2), TNBC (n = 8), and TAMR (n = 4), the relative expression of lncRNA IGF2-AS/GAPDH was significantly higher in TAMR breast cancer patients compared to patients with other subtypes (p < 0.01).